Skip to main content
Deutsch

Search

  1. Home
  2. Search

Webseiten-Inhalte

Plastic particles can increase intestinal inflammation ... harmful bacterial species.  Effects beyond the intestine "Furthermore, our study shows that under inflammatory conditions, MNPs not only accumulate in the intestine but also in other excretory organs such as the liver and kidneys, as well as in the bloodstream," explains study leader Lukas Kenner... https://www.meduniwien.ac.at/web/en/about-us/news/2026/news-in-january-2026/plastic-particles-can-increase-intestinal-inflammation/
Plastic particles can increase intestinal inflammation ... harmful bacterial species.  Effects beyond the intestine "Furthermore, our study shows that under inflammatory conditions, MNPs not only accumulate in the intestine but also in other excretory organs such as the liver and kidneys, as well as in the bloodstream," explains study leader Lukas Kenner... https://www.meduniwien.ac.at/web/en/about-us/news/2026/news-in-january-2026/plastic-particles-can-increase-intestinal-inflammation/medicine-science/
Prostate cancer: two proteins identified as novel markers of greater aggressiveness ... suffer an aggressive course and often fatal outcome. The joint study conducted by a research team led by Robert Wiebringhaus and supervised by Lukas Kenner from MedUni Vienna's Department of Pathology and the Department of Laboratory Animal Pathology at Vetmeduni, member of the Executive Board of the... https://www.meduniwien.ac.at/web/en/ueber-uns/news/2021/news-im-dezember-2021/prostatakarzinom-zwei-proteine-als-neue-indikatoren-fuer-aggressiveres-verhalten-identifiziert/medicine-science/
Prostate cancer: two proteins identified as novel markers of greater aggressiveness ... suffer an aggressive course and often fatal outcome. The joint study conducted by a research team led by Robert Wiebringhaus and supervised by Lukas Kenner from MedUni Vienna's Department of Pathology and the Department of Laboratory Animal Pathology at Vetmeduni, member of the Executive Board of the... https://www.meduniwien.ac.at/web/en/ueber-uns/news/2021/news-im-dezember-2021/prostatakarzinom-zwei-proteine-als-neue-indikatoren-fuer-aggressiveres-verhalten-identifiziert/
New therapeutic approach for anaplastic large cell lymphoma ... Lukas Kenner (MedUni Vienna and Vetmeduni Vienna) has now identified a new biomarker and therapeutic approach with the protein PDGFRβ. In this study, Ines Garces de los Fayos Alonso and others describe that the STAT3/5 signaling pathway is downstream of the PDGFRβ protein and is partly responsible for these tumors becoming more aggressive. Lukas Kenner summarizes the conclusions: "We have found PDGFRβ as a new biomarker and consider PDGFRβ-STAT3/5 signaling to be the central factor in aggressive ALCL tumors. Furthermore, we assume that inhibition of PDGFRβ and/or STAT3/5 will massively improve... https://www.meduniwien.ac.at/web/en/about-us/news/2022/news-in-september-2022/neuer-therapieansatz-beim-anaplastisch-grosszelligen-lymphom/medicine-science/
Neuer Therapieansatz beim anaplastisch-großzelligen Lymphom ... regulieren das Protein PDGFRβ. Protein PDGFRβ beschleunigt Tumorwachstum Eine aktuelle internationale Studie unter der Leitung von Sabine Lagger (Vetmeduni Wien) und Lukas Kenner (MedUni Wien und Vetmeduni Wien) hat nun mit dem Protein PDGFRβ einen neuen Biomarker und Therapieansatz identifiziert. In dieser Studie beschreiben Ines Garces de los Fayos Alonso und das Autor:innenteam, dass der STAT3/5 Signalweg dem Protein PDGFRβ nachgeschaltet und mit dafür verantwortlich ist, dass diese Tumore aggressiver werden. Lukas Kenner vom Klinischen Institut für Pathologie der MedUni Wien fasst die Schlussfolgerungen... https://www.meduniwien.ac.at/web/ueber-uns/news/news-im-september-2022/neuer-therapieansatz-beim-anaplastisch-grosszelligen-lymphom-1/medizin-wissenschaft/
New therapeutic approach for anaplastic large cell lymphoma ... Lukas Kenner (MedUni Vienna and Vetmeduni Vienna) has now identified a new biomarker and therapeutic approach with the protein PDGFRβ. In this study, Ines Garces de los Fayos Alonso and others describe that the STAT3/5 signaling pathway is downstream of the PDGFRβ protein and is partly responsible for these tumors becoming more aggressive. Lukas Kenner summarizes the conclusions: "We have found PDGFRβ as a new biomarker and consider PDGFRβ-STAT3/5 signaling to be the central factor in aggressive ALCL tumors. Furthermore, we assume that inhibition of PDGFRβ and/or STAT3/5 will massively improve... https://www.meduniwien.ac.at/web/en/about-us/news/2022/news-in-september-2022/neuer-therapieansatz-beim-anaplastisch-grosszelligen-lymphom/
Neuer Therapieansatz beim anaplastisch-großzelligen Lymphom ... regulieren das Protein PDGFRβ. Protein PDGFRβ beschleunigt Tumorwachstum Eine aktuelle internationale Studie unter der Leitung von Sabine Lagger (Vetmeduni Wien) und Lukas Kenner (MedUni Wien und Vetmeduni Wien) hat nun mit dem Protein PDGFRβ einen neuen Biomarker und Therapieansatz identifiziert. In dieser Studie beschreiben Ines Garces de los Fayos Alonso und das Autor:innenteam, dass der STAT3/5 Signalweg dem Protein PDGFRβ nachgeschaltet und mit dafür verantwortlich ist, dass diese Tumore aggressiver werden. Lukas Kenner vom Klinischen Institut für Pathologie der MedUni Wien fasst die Schlussfolgerungen... https://www.meduniwien.ac.at/web/ueber-uns/news/news-im-september-2022/neuer-therapieansatz-beim-anaplastisch-grosszelligen-lymphom-1/
2023 Dezember - Tanja Limberger | MedUni Wien ... Arbeitsgruppe von Univ.-Prof. Dr.med.univ. Lukas Kenner im Zuge eines gemeinsamen Projektes mit CBmed (Center for Biomarker Research in Medicine) und in Zusammenarbeit mit der Universitätsklinik für Radiologie und Nuklearmedizin der MedUni Wien, dem Central European Institute of Technology an der Masaryk... https://www.meduniwien.ac.at/web/forschung/researcher-of-the-month/2023-dezember-tanja-limberger/
Detailsite | MedUni Vienna ... eine Auszeichnung der Europäischen Gesellschaft für Urologische Forschung (ESUR) im Jahre 2010 und vom Comprehensive Cancer Center (CCC) der MedUni Wien (2011) erhalten. Pencik arbeitet seit 2010 am Ludwig Boltzmann Institut für Krebsforschung unter der Leitung von Lukas Kenner. Share Whatsapp... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/in-german-hohe-auszeichnung-der-artp-fuer-jan-pencik/